Ledgy AG is a technology company based in Zurich, Switzerland, founded in 2017. It operates a Software-as-a-Service platform designed to facilitate the management and exchange of securities in private companies. The platform serves as an online share register, enabling founders, employees, and investors to manage equity effectively. Ledgy's tools allow companies to oversee employee incentive plans, model financing rounds, and generate reports for investors, thereby fostering trust in capital tables. The platform features personalized dashboards for employees to track their vested shares and for investors to monitor portfolio performance. By digitizing the equity management process and ensuring error-free capital tables, Ledgy provides clarity and insights for all stakeholders involved, ultimately supporting companies in attracting and retaining talent while enhancing investor relations.
Morgen is a time management platform that simplifies the scheduling process by integrating multiple calendars and task management tools into a single application. As the complexity of time management increases, Morgen addresses this challenge by offering a holistic solution that allows users to plan, organize, and optimize their schedules effectively. The platform combines various calendar systems and communication channels, enabling users to manage all events, tasks, lists, and reminders in one place. With its native scheduling tool, Morgen helps individuals and teams reduce meeting chaos and streamline their daily activities, making time management more efficient and less fragmented.
Picterra SA operates an online platform that automates artificial intelligence (AI) workflows for object detection to extract geo-information. Founded in 2016 and headquartered in Écublens, Switzerland, the company integrates AI with satellite, drone, and aerial data to help users monitor and anticipate environmental changes. Picterra serves various sectors, including aerial imaging and mapping, financial services, insurance, journalism, precision agriculture, real estate, utilities, infrastructure, as well as public organizations and NGOs. The platform is designed to empower users by allowing them to train and customize AI models without requiring programming or deep learning expertise, thus facilitating the extraction of relevant geo-information tailored to their specific needs.
Altoida AG, founded in 2016 and based in Lucerne, Switzerland, develops a healthcare platform and application specifically for Alzheimer’s patients. The Altoida application is the first validated solution designed to predict the risk of Alzheimer’s disease before symptoms appear, providing healthcare professionals with objective measurements of cognitive performance. The platform utilizes an augmented reality framework to conduct various tests that assess spatial memory, prospective memory, and executive functions. These tests can identify early and subtle cognitive changes up to six years prior to the onset of typical neurodegenerative symptoms. The Altoida Neuro Motor Index (NMI) serves as an active digital biomarker for early detection of cognitive and functional changes. The application is intended for patients aged 62 and older and is used as an adjunctive tool to evaluate perceptual and memory function. Results from the tests are accessible in real-time via a secure web-based dashboard, ensuring compliance with HIPAA regulations. Altoida's innovative approach aims to make brain health assessments more affordable, accessible, and actionable for doctors, researchers, and healthcare providers.
turicode Inc. develops software as a service (SaaS) platform for document processing. Its software reads and understands documents such as PDFs, scans, and emails. The company’s MINT.extract platform helps companies and their employees to digitize document. It serves legal and tax, financial industry, healthcare, logistics, insurance, and archives industries. turicode Inc. was founded in 2016 and is based in Winterthur, Switzerland.
Ledgy AG is a technology company based in Zurich, Switzerland, founded in 2017. It operates a Software-as-a-Service platform designed to facilitate the management and exchange of securities in private companies. The platform serves as an online share register, enabling founders, employees, and investors to manage equity effectively. Ledgy's tools allow companies to oversee employee incentive plans, model financing rounds, and generate reports for investors, thereby fostering trust in capital tables. The platform features personalized dashboards for employees to track their vested shares and for investors to monitor portfolio performance. By digitizing the equity management process and ensuring error-free capital tables, Ledgy provides clarity and insights for all stakeholders involved, ultimately supporting companies in attracting and retaining talent while enhancing investor relations.
CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.
iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
Smart Valor AG, founded in 2017 and based in Zug, Switzerland, is a blockchain startup focused on creating a decentralized marketplace for tokenized alternative investments. It facilitates the issuance and distribution of investment solutions and banking services, enabling banks to connect directly with a diverse network of investors. The platform offers secure custody for crypto assets and provides accessible, tokenized investments across various sectors, including real estate, currencies, and venture capital. Additionally, Smart Valor integrates services related to compliance and performance tracking within its decentralized framework. By leveraging the Swiss legal framework, the company aims to combine the security of traditional banking with the innovative potential of blockchain technology.
Gamaya SA specializes in farmland analytics solutions aimed at enhancing the efficiency and sustainability of both large industrial farms and small-holder operations. Founded in 2015 and based in Lausanne, Switzerland, the company offers a range of tools tailored to specific crops, including SOYFIT for soybean cultivation and CANEFIT for sugarcane. Their Agronomic Intelligence Platform serves large-scale tobacco growers. By leveraging advanced technologies such as hyperspectral imaging, embedded cameras, and analytical software, Gamaya provides farmers with actionable insights for early detection of diseases, pests, and stress, as well as monitoring growth and optimizing fertilization. This approach enables better decision-making regarding the use of chemicals and fertilizers, ultimately improving yield while minimizing environmental impact.
Altoida AG, founded in 2016 and based in Lucerne, Switzerland, develops a healthcare platform and application specifically for Alzheimer’s patients. The Altoida application is the first validated solution designed to predict the risk of Alzheimer’s disease before symptoms appear, providing healthcare professionals with objective measurements of cognitive performance. The platform utilizes an augmented reality framework to conduct various tests that assess spatial memory, prospective memory, and executive functions. These tests can identify early and subtle cognitive changes up to six years prior to the onset of typical neurodegenerative symptoms. The Altoida Neuro Motor Index (NMI) serves as an active digital biomarker for early detection of cognitive and functional changes. The application is intended for patients aged 62 and older and is used as an adjunctive tool to evaluate perceptual and memory function. Results from the tests are accessible in real-time via a secure web-based dashboard, ensuring compliance with HIPAA regulations. Altoida's innovative approach aims to make brain health assessments more affordable, accessible, and actionable for doctors, researchers, and healthcare providers.
MESA Imaging specializes in the development and production of 3D time-of-flight cameras designed to capture full 3D images at video frame rates. The company utilizes the Time-of-Flight (TOF) principle and incorporates advanced technologies, such as the silo pixel architecture and the SR4000 sensor chip, to enhance distance measurement capabilities. MESA Imaging supplies its innovative camera systems to various sectors, including video gaming, machine vision, automotive, and robotics, thereby contributing to advancements in image-related industries.
Ledgy AG is a technology company based in Zurich, Switzerland, founded in 2017. It operates a Software-as-a-Service platform designed to facilitate the management and exchange of securities in private companies. The platform serves as an online share register, enabling founders, employees, and investors to manage equity effectively. Ledgy's tools allow companies to oversee employee incentive plans, model financing rounds, and generate reports for investors, thereby fostering trust in capital tables. The platform features personalized dashboards for employees to track their vested shares and for investors to monitor portfolio performance. By digitizing the equity management process and ensuring error-free capital tables, Ledgy provides clarity and insights for all stakeholders involved, ultimately supporting companies in attracting and retaining talent while enhancing investor relations.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Altoida AG, founded in 2016 and based in Lucerne, Switzerland, develops a healthcare platform and application specifically for Alzheimer’s patients. The Altoida application is the first validated solution designed to predict the risk of Alzheimer’s disease before symptoms appear, providing healthcare professionals with objective measurements of cognitive performance. The platform utilizes an augmented reality framework to conduct various tests that assess spatial memory, prospective memory, and executive functions. These tests can identify early and subtle cognitive changes up to six years prior to the onset of typical neurodegenerative symptoms. The Altoida Neuro Motor Index (NMI) serves as an active digital biomarker for early detection of cognitive and functional changes. The application is intended for patients aged 62 and older and is used as an adjunctive tool to evaluate perceptual and memory function. Results from the tests are accessible in real-time via a secure web-based dashboard, ensuring compliance with HIPAA regulations. Altoida's innovative approach aims to make brain health assessments more affordable, accessible, and actionable for doctors, researchers, and healthcare providers.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
picoDrill SA provides micromachining techniques for production of hole structures in glass and dielectric materials. Its Electrothermal Selffocussing method allows the controlled heating and evaporation of precisely defined volumes in dielectric materials. The company is based in Lausanne, Switzerland.
Lambda Health System SA specializes in the development and commercialization of innovative rehabilitation technology, particularly focusing on a robotic device known as the Lambda Robot. This device is designed to assist patients with locomotor disabilities, facilitating rehabilitation across various fields including neurorehabilitation, orthopedics, and geriatrics. The Lambda Robot allows therapists to perform exercises without the need for patient transfers between different machines, streamlining the rehabilitation process. Additionally, the company offers the Lambda Control Center, a platform that enables physicians to tailor exercises to individual patient needs while monitoring their progress and adjusting training parameters as necessary. The control center also incorporates engaging games and virtual reality applications aimed at addressing cognitive disorders. Founded in 2015 and based in Yverdon-Les-Bains, Switzerland, Lambda Health System emerged as a spin-off from the University of Applied Sciences of Canton de Vaud, focusing on creating cost-effective and user-friendly rehabilitation solutions.
Advanon AG, based in Zurich, Switzerland, operates an online financial services platform that specializes in invoice financing for small and medium-sized enterprises (SMEs). Founded in 2015, the platform allows businesses to pre-finance their invoices, enabling them to access liquidity without the long wait times typically associated with customer payments, which can range from 30 to 120 days. This service provides SMEs with flexible financing options that help strengthen their cash flow and support growth. Advanon is recognized as a financial intermediary and complies with regulatory standards set by the Swiss Financial Market Supervisory Authority (FINMA) under the Anti Money Laundering Act.
Altoida AG, founded in 2016 and based in Lucerne, Switzerland, develops a healthcare platform and application specifically for Alzheimer’s patients. The Altoida application is the first validated solution designed to predict the risk of Alzheimer’s disease before symptoms appear, providing healthcare professionals with objective measurements of cognitive performance. The platform utilizes an augmented reality framework to conduct various tests that assess spatial memory, prospective memory, and executive functions. These tests can identify early and subtle cognitive changes up to six years prior to the onset of typical neurodegenerative symptoms. The Altoida Neuro Motor Index (NMI) serves as an active digital biomarker for early detection of cognitive and functional changes. The application is intended for patients aged 62 and older and is used as an adjunctive tool to evaluate perceptual and memory function. Results from the tests are accessible in real-time via a secure web-based dashboard, ensuring compliance with HIPAA regulations. Altoida's innovative approach aims to make brain health assessments more affordable, accessible, and actionable for doctors, researchers, and healthcare providers.
Inositec AG is a biotechnology company based in Zurich, Switzerland, established in 2015 as a spin-off from ETH Zurich. The company specializes in the development of drug therapies derived from its proprietary Inositune platform, which utilizes inositol phosphate analogs with adjustable properties. Inositec's lead product, INS-5010, is a non-antibiotic therapy designed to target colon infections caused by Clostridium difficile. Additionally, the company addresses soft tissue calcification disorders, focusing on vascular and renal calcification, including orphan indications. By selectively modifying the phosphate groups in inositol phosphate compounds, Inositec aims to create molecules with improved drug-like properties tailored for specific therapeutic applications.
Gamaya SA specializes in farmland analytics solutions aimed at enhancing the efficiency and sustainability of both large industrial farms and small-holder operations. Founded in 2015 and based in Lausanne, Switzerland, the company offers a range of tools tailored to specific crops, including SOYFIT for soybean cultivation and CANEFIT for sugarcane. Their Agronomic Intelligence Platform serves large-scale tobacco growers. By leveraging advanced technologies such as hyperspectral imaging, embedded cameras, and analytical software, Gamaya provides farmers with actionable insights for early detection of diseases, pests, and stress, as well as monitoring growth and optimizing fertilization. This approach enables better decision-making regarding the use of chemicals and fertilizers, ultimately improving yield while minimizing environmental impact.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Equippo is a commercial equipment company that specializes in buying and selling used construction equipment through its online marketplace. Founded in 2014 and headquartered in Zug, Switzerland, the company connects manufacturers, dealers, leasing companies, and other trusted sellers with buyers worldwide, including regions such as South America, Russia, and Poland. Equippo's platform simplifies the process by offering services such as machine inspection, payment management, shipping, trucking, and customs clearance. A notable feature of its service is the Equippo final price calculation engine, which incorporates tariffs, transport, and logistics specific to the buyer's region, making international transactions more straightforward. With a team that can communicate in over nine languages, Equippo aims to facilitate transparent trading in the heavy equipment sector.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.
Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has built a diverse pipeline based on proprietary technology platforms developed in collaboration with institutions such as the University of Zürich and the California Institute of Technology. The company's offerings include Neuroseal, a biomaterial for dural sealing currently undergoing CE marking review in the EU, and MagnetOs Granules and Putty, approved for orthopedic, spinal, and dental applications in both the EU and the US. Kuros has an active clinical program, having conducted trials involving over 600 patients with promising results in various indications. Furthermore, Kuros has engaged in collaborations to advance its research, including work on CYT003 for oncology. Positioned for growth, Kuros is transitioning towards commercial operations, with plans for additional product approvals in the near future.
L.E.S.S. designs and manufactures thinner, brighter, more uniform technical lighting systems. Thanks to our innovative approach, our aim is to deliver our customer with lighting systems that provide both intense and uniform light within a small form factor.
Genkyotex SA is a biopharmaceutical company based in Labège, France, focusing on the development of innovative oral small molecule therapies that selectively inhibit NOX enzymes implicated in various disease processes. The company's lead candidate, GKT831, is a NOX1 and NOX4 inhibitor undergoing Phase II clinical trials for primary biliary cholangitis, a fibrotic orphan disease, and type 1 diabetes with kidney complications. In addition, Genkyotex is advancing GKT771, a preclinical NOX1 inhibitor aimed at addressing pain processing and inflammation. The company also holds a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for developing multivalent combination vaccines against infectious diseases. Genkyotex's technology is designed to treat oxygen-radical mediated acute and chronic diseases, offering improved specificity and safety compared to existing antioxidant therapies, and targets cardiovascular, metabolic, and neurodegenerative conditions. Founded in 2006, Genkyotex is committed to enhancing patient outcomes through its research and development initiatives.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Sonic Emotion AG, founded in 2002 and headquartered in Zurich, Switzerland, specializes in advanced audio solutions that create immersive sound experiences. The company's flagship technology, Sonic Emotion Absolute 3D, enables natural 3D sound reproduction using sound field control from as few as two channels, allowing for compact audio setups suitable for a variety of environments. Sonic Emotion AG caters to diverse markets, providing audio solutions for 3D cinemas, events, trade fairs, museums, theme parks, and dance shows. Additionally, the company offers audio simulation services, OEM licensing solutions, and a sound enhancement application named Headquake for Apple i-device products. With research facilities in France and sales offices across Asia, including China, Hong Kong, Taiwan, and Japan, Sonic Emotion AG is positioned to deliver cutting-edge audio technology globally.
Windeln.de operates as an online retailer specializing in products for babies, toddlers, children, and young mothers, serving markets in Germany, Austria, Switzerland, the Czech Republic, Spain, and China. The company offers a diverse range of products, including diapers, baby food, clothing, toys, strollers, child car seats, and baby monitors, as well as children's furniture. Additionally, it provides items for older children and parents, encompassing dietary supplements and cosmetics. Windeln.de's business is structured into segments that include a German shop, international shops, and shopping clubs, catering to a broad customer base across Europe and China.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Nexthink S.A. is a leader in end-user experience management, focusing on enhancing digital workplaces through real-time analytics and employee feedback. The company provides a comprehensive platform that transforms endpoint data into actionable insights, enabling organizations to identify, diagnose, and resolve issues effectively. Its offerings include solutions for incident and problem management, change management, and a Digital Experience Score that combines quantitative data and user input to assess and enhance the digital workplace experience. Nexthink serves a diverse range of sectors, including education, finance, healthcare, and manufacturing, catering to Global 5000 organizations both in Switzerland and internationally. Established in 2004 and headquartered in Prilly, Switzerland, Nexthink operates across the United States, Europe, the Middle East, and Asia Pacific.
SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.
SilentSoft SA, founded in 2000 and headquartered in Morges, Switzerland, specializes in telemetry solutions that facilitate automated real-time communication between connected devices. The company offers a range of products, including StockView, a stock optimization solution for energy distributors, property managers, and end customers, and IndexView, designed for energy efficiency in properties. SilentSoft also provides monitoring devices for tanks and meters, enabling clients to receive real-time data and improve operational efficiency by reducing emergency deliveries and lowering carbon emissions. With additional offices in Meudon, France, and Willstätt, Germany, SilentSoft serves a diverse clientele across European countries, positioning itself as a key player in the Machine to Machine (M2M) industry.
CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Nexthink S.A. is a leader in end-user experience management, focusing on enhancing digital workplaces through real-time analytics and employee feedback. The company provides a comprehensive platform that transforms endpoint data into actionable insights, enabling organizations to identify, diagnose, and resolve issues effectively. Its offerings include solutions for incident and problem management, change management, and a Digital Experience Score that combines quantitative data and user input to assess and enhance the digital workplace experience. Nexthink serves a diverse range of sectors, including education, finance, healthcare, and manufacturing, catering to Global 5000 organizations both in Switzerland and internationally. Established in 2004 and headquartered in Prilly, Switzerland, Nexthink operates across the United States, Europe, the Middle East, and Asia Pacific.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.
Nexthink S.A. is a leader in end-user experience management, focusing on enhancing digital workplaces through real-time analytics and employee feedback. The company provides a comprehensive platform that transforms endpoint data into actionable insights, enabling organizations to identify, diagnose, and resolve issues effectively. Its offerings include solutions for incident and problem management, change management, and a Digital Experience Score that combines quantitative data and user input to assess and enhance the digital workplace experience. Nexthink serves a diverse range of sectors, including education, finance, healthcare, and manufacturing, catering to Global 5000 organizations both in Switzerland and internationally. Established in 2004 and headquartered in Prilly, Switzerland, Nexthink operates across the United States, Europe, the Middle East, and Asia Pacific.
Visonys
Venture Round in 2006
Visonys develops information security software for financial institutions, e-commerce, industrial companies, and authorities. It offers visonysAirlock, which provides differing authorization to clients, partners, and employees for relevant applications. The company's products are used in Web applications that process confidential information or manage business transactions and processes. The company was founded in 2002 as Seclutions AG and changed its name to Visonys AG in February, 2006. The company is based in Zurich, Switzerland.
Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has built a diverse pipeline based on proprietary technology platforms developed in collaboration with institutions such as the University of Zürich and the California Institute of Technology. The company's offerings include Neuroseal, a biomaterial for dural sealing currently undergoing CE marking review in the EU, and MagnetOs Granules and Putty, approved for orthopedic, spinal, and dental applications in both the EU and the US. Kuros has an active clinical program, having conducted trials involving over 600 patients with promising results in various indications. Furthermore, Kuros has engaged in collaborations to advance its research, including work on CYT003 for oncology. Positioned for growth, Kuros is transitioning towards commercial operations, with plans for additional product approvals in the near future.
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.
Xigen SA is a private Swiss biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) in Switzerland. Dr. Christophe Bonny, CEO and co-founder, is a renowned molecular biologist with over a decade's research expertise on intracellular peptides and signalling.
Covalys Biosciences
Series B in 2005
Covalys Biosciences AG engages in the development and production of tools for protein research. It also provides protein labeling products. The company was founded in 2002 and is based in Witterswil, Switzerland.
Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has built a diverse pipeline based on proprietary technology platforms developed in collaboration with institutions such as the University of Zürich and the California Institute of Technology. The company's offerings include Neuroseal, a biomaterial for dural sealing currently undergoing CE marking review in the EU, and MagnetOs Granules and Putty, approved for orthopedic, spinal, and dental applications in both the EU and the US. Kuros has an active clinical program, having conducted trials involving over 600 patients with promising results in various indications. Furthermore, Kuros has engaged in collaborations to advance its research, including work on CYT003 for oncology. Positioned for growth, Kuros is transitioning towards commercial operations, with plans for additional product approvals in the near future.
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.
Avalon Photonics
Venture Round in 2003
Avalon Photonics produces world-class VCSELs (vertical cavity surface emitting lasers) for datacom, sensing, and measurement markets. These devices are enabling volume applications due to their exceptional performance, lower power consumption, and volume cost reduction.Avalon also produces unique, patent-protected, single-spatial-mode VCSELs with unsurpassed specifications required for many sensing and measurement applications. Avalon’s ISO 9001 production line achieves high quality, exceptional uniformity, and telecom-grade reliability devices. VCSELs can be provided from bare die up to fully packaged units with temperature control and fiber pigtailing.